Home
overview

SMi Group proudly presents the inaugural launch of 3D Cell Culture, an exciting new conference scheduled to take place on the 22nd and 23rd February 2017, London UK. Following the success of our Advances in Cell Based Assays series, 3D Cell Culture is set to become a leading event for industry. 3D Cell Culture 2017 will address the latest developments of 3D cell culture techniques; the ways in which predictive 3D models are presently paving the way to future technologies, and the ways in which they are currently revolutionizing drug discovery and screening and disease modelling. The 3D cell culture market is predicted to reach $3702.2 million by 2021* with main increase seen in novel technologies and culture methods. This event will highlight emerging technologies, like 3D and 4D bio imaging, and their application in furthering research and medical practice. In addition, there will be focus on organoid technology and the involvement of 3D culture methods in drug and toxicology screening, topics of great current commercial interest to pharmaceutical and research bodies. *Source: http://prn.to/1R0Uq7j

3D Cell Culture 2017 will bring together leading professionals and researchers in the industry to discuss the latest developments and future potential of this technique. 3D Cell Culture 2017 will present success stories 3D culture applications, identifying the newest and brightest technologies, and the translation of 3D models into successful clinical and industrial applications. There will be emphasis on the success and future of 3D methods in organoid research, disease modeling and toxicology screening, stem cell research, and much more.

We look forward to meeting you in February!

  • Hear from industry and research leaders on the latest in 3D cell culture
  • What are the latest technologies available to 3D cell culture?
  • Which techniques are harnessing greatest success and predictability?
  • What are the current challenges to 3D cell culture?
  • Sanofi Aventis give a technology update and comparisons of the latest technology available to 3D cell culture
  • Insights into high throughput screening, and the use of CRISPR in 3D cultures from Novartis
  • Harnessing organoid technology for personalized models of drug discovery with the HUB
  • Hear GlaxoSmithKline on the use of 3D cell culture in toxicity investigations
  • Compare the benefit and potential of 3D cell culture over 2D cell culture with our chair, Stefan Przyborski
  • Drug discovery and target validation case study with AstraZeneca

Who should attend?

Directors, Supervisors, Specialists, Principal Scientists, Product Managers, Science Officer, Chief Scientific Officer, CEO, COO, Project Manager, Lead Scientists, Senior Scientists, Project leaders, Labheads, Research Scientists, Engineers, Senior Pharmacologists, Professors in the following areas:

  • Cell culture
  • Stem cell and regenerative medicine
  • Process development - early and late stage
  • Large scale manufacturing
  • Cell therapy
  • Cell technology
  • High Throughput Screening
  • Assay development and screening
  • Business development

 

<p>A B A France; AstraZeneca; BIAL - Portela &amp; C&ordf;; DCPrime; Domain Therapeutics; Fraunhofer-IME; German Cancer Research Center (DKFZ)<br /> GlaxoSmithKline; Heptares Therapeutics; InSphero; Ipsen; Johns Hopkins University School of Medicine; King's College London; Medicyte; <br /> Medimmune; Olympus Corporation; Ono Pharmaceutical; Plasticell; Progenitor Therapeutics; Rottapharm; Sanofi Winthrop; Sanofi-Synthelabo Recherch&eacute;; Sigma Aldrich; Stemmatters; STRATEC Biomedical; TDI-NDM Oxford; The Electrospinning Company; UCB Group<br /> University of Bern; University of Ferrara; Viscofan Bioengineering<br /> &nbsp;</p>

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Stefan Przyborski

Stefan Przyborski, Founder and CSO, Durham University
View Bio

9:10 An introduction to 3D methods; Challenges, changes, and the relationships between science and technology

Stefan Przyborski

Stefan Przyborski, Founder and CSO, Durham University
View Bio

• 2D vs 3D cell culture debate
• Review of alternative approaches and the development of new technologies
• Challenges facing 3D culture methods, in terms of technologies available and methods used
• Showcase applications where 3D technology makes a difference
• Future perspective for 3D cell culture technology and further development

 

 

 

9:50 Bridging the gap between 2D and in vivo: tumour spheroid-based assays for target validation and screening

Radek Polanski

Radek Polanski, Senior Research Scientist , AstraZeneca
View Bio

• Drug discovery project-related examples of the 2D-3D disconnection with in vivo validation
• Application of a 3D culture technique for analysis of a functional predictive biomarker for the IAPi/TRAIL combination treatment as an alternative to the analysis of expression of single or multiple biomarkers in highly redundant cell death pathways
• Generation of best practice guidelines and development of the platform for screening in tumour spheroids

10:30 Morning Coffee

11:00 Novel tools and techniques for successful 3D cell culture

Ute Vespermann

Ute Vespermann, Drug Discovery Specialist, Corning

11:40 Emerging technologies in 3D cell culture for drug discovery

Oliver Chao

Oliver Chao, Head, Emerging Biomedical Sciences, sanofi-aventis
View Bio

• The potential of 3D culture is dependent on and symbiotic with technology development
• Highlighting of emerging techniques available, focus on CRISPR and microfluidic techniques; overview and particular benefits in relation to 3D culture
• Current challenges to adoption of new technologies, why are new methods slow to be adopted?

12:10 Networking Lunch

13:30 Using 3D spheroids and microtissue methods to investigate hepatotoxicity

Carlo  Cusulin

Carlo Cusulin , Postdoctoral Researcher , Roche Diagnostics

• How using IPS cell lines refi nes disease modelling – patient specifi c screens
• Validating 3D models; can we prove that 3D is indeed an improvement and is physiology more relevant than previous methods?
• Overview of STEMBANCC

14:10 HipSci and the ‘Stem cell hotel’, an innovative platforms for collaborative phenotyping

Davide  Danovi

Davide Danovi, Director, HipSci Cell Phenotyping, Centre for Stem Cells and Regenerative Medicine, King's College London,, King's College London
View Bio

• Stem cells, high content analysis, drug discovery and disease models
• The ‘Human induced pluripotent stem cells initiative’
• Collaborative phenotyping

14:50 CRISPR engineered organoids for modelling genetic and infectious brain disease

Max Salick

Max Salick, Postdoctoral Researcher, Novartis Institutes For Biomedical Research

• Recent genetic advances allow us to rapidly produce isogenically-controlled disease stem cell lines
• These diseases manifest in cerebral organoids similarly to in the developing human brain
• Advanced imaging and sequencing methods allow us to closely investigate disease and treatment effects on
development
• Similar engineering techniques allow precise investigation of interactions between the specific proteins and
infectious disease

15:30 Afternoon Tea

16:00 Human in vitro 3D lung models for efficacy and toxicity assessment

Samuel Constant

Samuel Constant, COO, Epithelix

• Long term monitoring of effect on respiratory tract
• Disease models (Asthma; COPD; CF and Lung cancer)
• How predictive are in vitro 3D human lung models?

16:40 Using 3D spheroids and microtissue methods to investigate hepatotoxicity

Christopher Schofield

Christopher Schofield, Investigator, GSK

• Exploring a complex culture methods using patient liver cells
• How does this compare to in vivo models
• Moving forward to screening of compounds – how to achieve this?

17:20 Chairman’s Closing Remarks and Close of Day One

Stefan Przyborski

Stefan Przyborski, Founder and CSO, Durham University
View Bio

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Robert Vries

Robert Vries, Managing Director, Hubrecht Institute
View Bio

9:10 EU Regulatory considerations for the use of cells in drug manufacturing (quality focus)

Louise Bisset

Louise Bisset, Biopharmaceutical Quality Assessor, MHRA
View Bio

• Using culture cells in the development and manufacture of medicinal products
• General regulatory perspective on the use of 3D cultured cells
• Manufacturing requirements for clinical trials/MAA

9:50 3D organoid cultures: a personalised model for drug discovery as well as companion diagnostics

Robert Vries

Robert Vries, Managing Director, Hubrecht Institute
View Bio

• Increasing the use of patient-derived cultures in preclinical development has the potential to identify, and eliminate, drugs likely to fail in preclinical trials
• High failure rates remains one of the greatest challenges, and barriers, to pharmaceutical drug development
• Using 3D and organoid biobanks to develop preclinical drug development tools and clinical personalised diagnostics
• The use of organoid models has already lead to successful patient specifi c treatments of Cystic Fibrosis

10:30 Morning Coffee

11:00 Screening of Mouse Intestinal Crypt Cultures: A simple readout for complex biology

Olaf Galuba

Olaf Galuba, Scientist, Novartis Pharmaceuticals

• Case study: How mouse intestinal crypt cultures have been adapted to enable high throughput screening
• In this system, isolated crypts form “organoid structures” with a histological hierarchy recapitulating in vivo small intestinal epithelium were used to screen a focused library of compounds for their ability to help the crypts recover from irradiation
• A number of challenges facing the implementation of such assays (such as handling Matrigel, the limits of miniaturisation and assay reproducibility) will be discussed
• Screening allowed the identification of tool compounds with which to help characterise the organoid cultures, subsequently this revealed subtle changes in the organoid response over time. Preliminary characterisation of this change will be described

11:40 Multi-Organ on a chip technologies; potential impact on predictive substance testing

Reyk Horland

Reyk Horland, Head of Business Development, Tissuse G Mb H
View Bio

• Case study: How mouse intestinal crypt cultures have been adapt• ‘Human-on-a-chip’ technology allows us to closely study organoid interaction
• Allows more representative drug toxicity and efficacy screening. Could this be the end of preclinical trials as we know them?
• Closing the gap between in vivo and in vitro; the importance of highly physiologically relevant cultures and microenvironments

12:20 Networking Lunch

13:30 Organ printing and the potential of guided angiogenesis

William  Whitford

William Whitford, Strategic Solutions Leader, GE Healthcare

• Larger printed tissues require cells capable of angiogenesis in order to function, success in achieving functional vasculature has so far been limited
• Developing both appropriate microfluidics and the in vitro culture media needed for the production of the preimplanted scaffolds remains a challenge
• Future potential; transplants, regenerative medicine, printing in the fourth dimension

14:10 Leaving 2D behind – considerations and approaches to translating cell therapy manufacturing into 3D

Eytan Abraham

Eytan Abraham, Head of Research & Technology for Emerging Technologies, Lonza Incorporated

• Clinical and regulatory implications of transitioning methods from 2D to 3D
• How does cell type affect optimal method used
• Manufacturing considerations

14:50 Afternoon Tea

15:10 Automatic mechano-profiling of cells – A new angle on cancer cell assays

Nils Goedecke

Nils Goedecke, Founder, Microduits GmbH

• A short introduction to mechano-biology
• Basic measuring techniques for cell mechanics – like 3D micro-structured cell culture substrates
• Automatic mechano-profi ling platform technology (and its potential for bone cancer prognosis)

15:50 Fast 3D imaging in multiwell plates

Christopher Dunsby

Christopher Dunsby, Senior Lecturer, Imperial College

• Introduction to light sheet-based fl uorescence microscopy and oblique plane microscopy (OPM) for high speed 3D imaging in multiwell plates
• Examples of experimental data showing readouts of FRET biosensors in multicellular spheroids, including time-lapse 3D imaging in multiwell plates
• An overview of initial steps towards developing image
analysis approaches enabling 3D imaging cytometry in multiwall plates
• Discussion of future challenges in data analysis, storage and curation

16:30 Chairman’s Closing Remarks and Close of Day Two

Robert Vries

Robert Vries, Managing Director, Hubrecht Institute
View Bio

+

FEATURED SPEAKERS

Davide  Danovi

Davide Danovi

Director, HipSci Cell Phenotyping, Centre for Stem Cells and Regenerative Medicine, King's College London,, King's College London
Louise Bisset

Louise Bisset

Biopharmaceutical Quality Assessor, MHRA
Oliver Chao

Oliver Chao

Head, Emerging Biomedical Sciences, sanofi-aventis
Radek Polanski

Radek Polanski

Senior Research Scientist , AstraZeneca
Reyk Horland

Reyk Horland

Head of Business Development, Tissuse G Mb H
Robert Vries

Robert Vries

Managing Director, Hubrecht Institute
Stefan Przyborski

Stefan Przyborski

Founder and CSO, Durham University

Benedicte Gagny

Specialiste Application Culture Cellulaire Et Biologie, Sigma Aldrich
Benedicte Gagny

Carlo Cusulin

Postdoctoral Researcher , Roche Diagnostics
Carlo  Cusulin

Carlo Cusulin is a Postdoctoral fellow in the Disease Relevant Cellular Assays group at Roche innovation center Basel, Switzerland. He obtained his PhD at the University of Lund, Sweden working on neural stem cells in the context of cell replacement for stroke. After that, he did a postdoc in the lab of Prof. Sam Weiss at the University of Calgary, Canada, dealing with cancer stem cells in glioblastoma.
At Roche, Dr. Cusulin utilizes patient-derived stem cells to model Alzheimer's disease in vitro. Together with other members of the group, he is attempting to provide reproducible and scalable cellular models, to be used in drug discovery screens and to understand the pathological processes in a human, physiological context.
 

Christopher Dunsby

Senior Lecturer, Imperial College
Christopher Dunsby

Chris Dunsby is a Reader with a joint post between Photonics, Department of Physics and the Centre for Histopathology, Department of Medicine at Imperial. His research interests are centred on the application of photonics and ultrafast laser technology to biomedical imaging with an emphasis on quantitative fluorescence imaging, and include light sheet microscopy, multiphoton microscopy, multiparameter fluorescence imaging and fluorescence lifetime imaging.

Christopher Schofield

Investigator, GSK
Christopher Schofield

Chris Schofield is an investigator in the Protein and Cellular Sciences department at GlaxoSmithKline Research and Development, Stevenage. He obtained his undergraduate degree in Applied Biology from the University of Coventry. Joining GlaxoSmithKline in 1995 he has gained over 20 years industrial experience in protein expression supporting small molecule drug discovery. He specialised in development of laboratory and pilot plant scale mammalian and insect cell culture systems including large scale baculovirus, bacMam and other transient systems. His cell culture expertise contributed to the development and implementation of frozen cell technology and the use of frozen isolated mitochondria from cell lines for high throughput screening. He is currently investigating the use of precision cut tissue slices and 3D cell culture models in early drug discovery.

Davide Danovi

Director, HipSci Cell Phenotyping, Centre for Stem Cells and Regenerative Medicine, King's College London,, King's College London
Davide  Danovi

Davide Danovi holds an MD from University of Milan and a PhD in Molecular Oncology from the European Institute of Oncology where he demonstrated the causative role of the HdmX protein in human cancer. He completed his postdoctoral training working with Prof. Austin Smith and Dr. Steve Pollard at the University of Cambridge and at University College London where he developed a screening platform to isolate compounds active on human neural stem cells from normal or brain tumour samples. Prior to his current role, he worked as principal scientist at a novel biotechnology company founded to isolate drugs for regenerative medicine using innovative stem cell technologies.

Eytan Abraham

Head of Research & Technology for Emerging Technologies, Lonza Incorporated
Eytan Abraham

Dr. Eytan Abraham heads the Emerging Technologies Business Unit Research & Technology (R&T) at Lonza, Inc. The group develops and tests enabling technologies and methods to facilitate manufacturing of cell therapies (allogeneic and autologous), viral therapies, and drug-antibody conjugates for clinical trials and commercial use.
Previously Dr. Abraham was Head of product innovation at the cell therapy company Pluristem Therapeutics.
Dr. Abraham holds a Ph.D. in developmental biology from the University of Maryland and a post-doctorate in tissue engineering and cell therapy at the Harvard-MIT Biomedical Engineering Center (HST) and Harvard Medical School.
 

Louise Bisset

Biopharmaceutical Quality Assessor, MHRA
Louise Bisset


Dr Louise Bisset obtained her PhD in Biochemistry (1996) from the University of Newcastle-Upon-Tyne, studying the molecular biology of gene expression where she gained in-depth knowledge of protein production and bioanalytical techniques. This was followed by 5 years as senior research scientist at Protherics Molecular Design Ltd (1996-2001) where she expanded the bioanalytical testing laboratory for the early identification of novel drug candidates. In 2001, Dr Bisset joined the analytical development laboratory of Cancer Research UK (Cancer Research Technology) where she lead a team of assay development scientists engaged in translational research. During that time she developed an interest in regulation and joined the UK’s medicines regulatory agency (the MHRA) as a pharmaceutical assessor in 2008. Dr Bisset is involved in the pre-and post-licensing approval of all types of biological medicinal products, with a special interests in cellular therapies, providing both National and European Scientific Advice.
 

Martin Guldenagel

Senior Techical Support Specialist, Corning, Inc
Martin Guldenagel

Max Salick

Postdoctoral Researcher, Novartis Institutes For Biomedical Research
Max Salick

Max Salick is a postdoctoral researcher in the Neuroscience Department of the Novartis Institutes for Biomedical Research in Cambridge, USA. Max entered the fields of stem cell biology and disease modeling from an engineering background, having received his PhD from the University of Wisconsin – Madison while researching the biomechanics of stem cell-derived cardiomyocytes. At Novartis, Max has taken a technology-intensive approach to the modeling of developmental neurological diseases. By combining CRISPR engineering, 3D organoid modeling, next-generation sequencing and imaging methods, he is investigating the roles of both genetic and infectious diseases in neurodevelopment. His current focuses are on tuberous sclerosis and the Zika virus, though these techniques are easily adaptable to a wide range of targets.

Nils Goedecke

Founder, Microduits GmbH
Nils Goedecke

Dr Nils Goedecke is a biophysicist by training and works on microsystem engineering for biological applications since 1996. After finishing his biophysics degree at Humboldt University Berlin he did his PhD in analytical chemistry at Imperial College London focussing on chip-based separation methods. Early 2003 he followed an invitation to work at the Massachusetts Institute of Technology (MIT), where he joined the bioengineering group of Prof P. Matsudaira. There he co-developed a microfluidic chip-based instrument for forensic DNA finger printing. End 2005 he returned to Europe joining the group of Prof A. Hierlemann at ETH Zurich as group leader for microfluidics working on instrumentation for single-cell analysis in systems biology. 2008 his focus returned to microstructured surfaces for cell adhesion guidance and cell mechanics readout. In 2010 he co-founded the ETH spin-off MicroDuits where he leads the product and application development for mechanosensitive cell based assays. Since 2012 he collaborates with Prof Snedekers group at the University Hospital Balgrist with focus on mechano-profiling of bone cancer cells.

Olaf Galuba

Scientist, Novartis Pharmaceuticals
Olaf Galuba

Olaf Galuba grew up in Osnabrück, Lower Saxony in Germany and he studied a Diploma in Engineering (MSc) at the University of Applied Sciences, Jena studying Medical Engineering and Biotechnology. He then began work at Bayer, Wuppertal; where he was a scientist responsible for the development of high throughput screens and ultra-high throughput screening technologies. After 5 years Olaf joined Novartis as part of the lead identification screening group with a special interest in cell based assays and screens identifying modulators of GPCRs. Since 2010 he has been part of a screening group that has focused on target and pathway analysis to support the discovery of novel genes projects trying to discovery new therapies. During this time Olaf was also able to pursue his interesting natural products and target identification for these compounds. Subsequently his role has shifted towards supporting numerous discovery projects for the development of assays to characterize these drug discovery programs, using 3D complex tissue culture systems to more closely reflect the disease being studied.

Oliver Chao

Head, Emerging Biomedical Sciences, sanofi-aventis
Oliver Chao

Dr. Chao is Head of Emerging Biomedical Sciences/Responsable Partenariats in the Strategy & Business Development unit at Sanofi in France. Dr. Chao is a biochemist/molecular biologist by training, via Univ. of Illinois, Univ. of Chicago, and INSERM/College de France. He lives in Paris, while he cooks, drinks, and thinks globally.

Radek Polanski

Senior Research Scientist , AstraZeneca
Radek Polanski

Radoslaw completed his MSc in Biotechnology in 2005, followed by a PhD in cancer studies in Liverpool researching p53-MDM2 network in kidney cancer. During this time he developed passion for science and pharmacology in particular, which led to a postdoctoral work in the Clinical Experimental Pharmacology lab at the CRUK Manchester Institute working on cell metabolism, circulating tumour cells, cell death and vasculogenic mimicry. A short postdoc at Astrazeneca followed, looking for predictive biomarkers for combination treatments targeting cell death pathways and developing 3D tumour cell models to aid his studies. Radoslaw works in the Cell Biology and Profiling team in the Discovery Sciences in Cambridge, and continues to pursue to develop and apply advanced cell models in the investigation of cancer biology and for drug discovery with particular focus on modeling and elucidation of the mechanisms of drug sensitivity and resistance.

Reyk Horland

Head of Business Development, Tissuse G Mb H
Reyk Horland

Since 2010 Reyk is actively involved in the development of TissUse’s Multi-Organ-Chip platform for culture analysis of drug candidates, cosmetics, chemicals and consumer products. He currently holds the position of Head of Business Development at TissUse. Prior to TissUse Reyk studied Biotechnology at the Technische Universität Berlin and specialized in Medical Biotechnology. During his academic career he was involved in various tissue engineering programs, all with a focus on commercialisation of the respective products.

Robert Vries

Managing Director, Hubrecht Institute
Robert Vries

Dr Robert Vries studied biology in Utrecht (the Netherlands) and Kent University (UK). Subsequently, he got his PhD at the Leiden University Medical Center (The Netherlands) with Prof Dr van der Eb, for the study of gene regulation during oncogenic transformation. He then shifted his interest toward the study of development and stem cells, and joined the group of Gerald Crabtree at Stanford University (USA) to study neural stem cells. In 2007 he returned to the Netherlands to the lab of Prof Dr Hans Clevers to continue the study of stem cells.

The group of Dr Clevers had just discovered the stem cell of intestine in 2007. A breakthrough finding was new protocol for the expansion of intestinal stem cells in culture (organoids). This system formed the basis of protocols that were subsequently developed for other organs such as liver and pancreas but also generated novel disease models such as Cystic Fibrosis, IBD and cancer.

In 2011 Vries changed positions to assist Hans Clevers in the management of his academic group. At the same time he started to work to translate the organoid technology towards clinical and industrial applications. In this capacity he was one of the people who started the foundation Hubrecht Organoid Technology (HUB), of which he is currently the managing director.
 

Samuel Constant

COO, Epithelix
Samuel Constant

Dr. Samuel Constant is co-founder and Chief Operating Officer of Epithelix (http://www.epithelix.com) and Chief Executive Officer of OncoTheis (http://www.oncotheis.com) two Swiss biotech companies specialized in tissue engineering.

Epithelix is a leader for in vitro assessment of drug efficacy and toxicity on human respiratory tract. Epithelix has developed unique 3D in vitro human airway tissues and testing services for studying airway pathologies like Asthma, Cystic Fibrosis and Chronic Obstructive Pulmonary Diseases. Samuel is in charge of global management and business development of the company; he also deals with the external collaborations with private and public research groups and financial issues.

Within the past 10 years, Dr. Samuel Constant and his team have focused their research efforts on the development of novel in vitro approaches to study effect of inhaled xenobiotics on the human respiratory tract. His efforts have led to the development of methods for repeated toxicity testing of xenobiotics (90 Days repeated dose exposure), evaluation of respiratory absorption and metabolism, assessment of lung inflammation. Since 2006, Dr. Samuel Constant and his team have won 18 prizes for their scientific achievements, technological innovation, and business development.
 

Stefan Przyborski

Founder and CSO, Durham University
Stefan Przyborski

Professor Przyborski holds an academic position as Professor in Cell Technology at Durham University. He has over 25 years experience in cell biology with specific interests in cell culture technology, neuroscience and stem cell research. In recent years he has developed a multi-disciplinary approach through collaborative projects with physical scientists to develop novel ways of solving biological problems. He has formed alliances with pharmaceutical and biotech companies, has published over 100 scientific papers and has filed several patents. He is also the founder and Chief Scientific Officer of Reinnervate (now part of ReproCELL Europe), a biotechnology company founded in 2002 as a spinout from Durham University UK. The Company is developing new and innovative ways to manage the growth and function of cultured cells. Its enabling technologies have multiple applications and will be particularly relevant to the control of cell differentiation and function in vitro.

Ute Vespermann

Drug Discovery Specialist, Corning
Ute Vespermann

William Whitford

Strategic Solutions Leader, GE Healthcare
William  Whitford

Bill Whitford is Strategic Solutions Leader, GE Healthcare in Logan, UT with over 20 years experience in biotechnology product and process development. He joined the company as an R&D Leader developing products supporting protein biological and vaccine production in mammalian and invertebrate cell lines. Products he has commercialized include defined hybridoma and perfusion cell culture media, fed-batch supplements and aqueous lipid dispersions. An invited lecturer at international conferences, Bill has published over 250 articles, book chapters and patents in the bioproduction arena. He now enjoys such activities as serving on the editorial advisory board for BioProcess International.

Sponsors and Exhibitors

Official Media Partner

Supporters

Workshops

VENUE

Copthorne Tara Hotel

Scarsdale Place, Kensington, London, United Kingdom

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

HOTEL BOOKING FORM

Interview with Novartis

Download

Interview with AstraZeneca - Radoslaw Polanski

Download

Sponsors and Exhibitors


BioTek Instruments

Sponsors and Exhibitors
http://www.biotek.com/

BioTek is a worldwide leader in the design, manufacture, and distribution of innovative life science instrumentation including cell imaging systems, microplate readers, washers, dispensers, automated incubators, stackers and pipetting systems. Our products enable life science research by providing high performance, cost-effective analysis and quantification of biomolecules, biomolecular interactions and cellular structure and function across diverse applications.


CELLON

Sponsors and Exhibitors
http://www.cellon.lu/

CELLON is a rapidly growing company, established in 1987 to provide products and services to the vaccine production and bioprocessing industries. Areas of expertise include mammalian cell culture processes and the storage & transport of sterile liquids. Our success to-date has been built upon an understanding of the requirements this demanding business sector - which has lead to the formation of many collaborative relationships with our customers. Such partnerships have enabled us to develop a range of products to meet specific industry needs - in unique, often revolutionary, ways


Corning

Sponsors and Exhibitors
http://www.corning.com/lifesciences

Corning is a global manufacturer of tools and equipment for cell culture, genomics, drug discovery, and microbiology. Our Corning®, Falcon®, Axygen®, and Gosselin™ brands include: vessels and differentiated surfaces for cell culture and scale-up, media, liquid handling products, ADME/Tox products and services, and microbiology consumables.


Merck

Sponsors and Exhibitors
http://www.merckmillipore.com/

Merck KGaA of Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials with about 50,000 employees in 66 countries. The organization has extensive expertise in 3D cell culture including Organotypic cell culture inserts, specialty cells, matrices and instrumentation.


Thermo Fisher Scientific

Sponsors and Exhibitors
http://www.thermofisher.com/

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. Through our Gibco, Invitrogen and Thermo Scientific brands, we help customers accelerate innovation and enhance productivity.

Media Partners


Assay and Drug Development Technologies

Official Media Partner
http://www.liebertpub.com/overview/assay-and-drug-development-technologies/118/

Assay and Drug Development Technologies delivers access to the techniques and tools that enable new advances in early-stage screening, and lead to therapeutic compounds for drug discovery and development. This authoritative, rapidly peer-reviewed journal features original papers, application-oriented technology reviews, and reports in methodology and technology application.

Media Partners


Swiss Biotech Association

Supporters
http://www.swissbiotech.org/

The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


Labiotech.eu

Supporters
http://labiotech.eu

Labiotech.eu is the leading digital media covering the European Biotech industry. It is used by over 35,000 people monthly to keep a watch on the business and innovations of biotechnologies.


Medical News Today

Supporters
http://www.medicalnewstoday.com

Medical News Today is the largest independent medical and health news site on the web - with over 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact peter@medicalnewstoday.com or visit www.medicalnewstoday.com.


Pharmalicensing

Supporters
http://www.pharmalicensing.com

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


Mednous

Supporters
http://www.MedNous.com

MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


Inderscience Publishers

Supporters
http://www.inderscience.com

Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


Pharmaceutical Technology

Supporters
http://www.pharmaceutical-technology.com

Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


Absave

Supporters
http://www.absave.com

Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


SelectScience

Supporters
http://www.selectscience.net/register?utm_source=Media-Partner&utm_medium=Website&utm_campaign=SMI

SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover the latest drug discovery and development technologies, products and techniques with product reviews, videos, application notes and news articles. Become a member for free today.


Pharmavision

Supporters
http://www.pharmavision.co.uk

PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


International Pharmaceutical Industry

Supporters
http://www.ipimediaworld.com

IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


Labsave

Supporters
http://www.labsave.com

Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


Farmavita

Supporters
http://www.farmavita.net/

Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


Drug Discovery Today

Supporters
http://www.drugdiscoverytoday.com/

Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


Technology Networks

Supporters
http://www.technologynetworks.com

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


Pharmacircle

Supporters
http://www.pharmacircle.com

PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


Biosave

Supporters
http://www.Biosave.com

Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


Drug Development Technology

Supporters
http://www.drugdevelopment-technology.com

Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Copthorne Tara Hotel

Scarsdale Place
Kensington
London W8 5SR
United Kingdom

Copthorne Tara Hotel

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.